ReviewDigestive diseases and sciences2026
The Interplay Between Immunological Status and Gut Microbial Dysbiosis in the Development of the Symptoms of Irritable Bowel Syndrome: A Systematic Review with Meta-Analysis.
Review in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A Novel Mixture ContainingInternational journal of molecular sciences · 2026Article
- High-resolution metagenomic characterization of gut microbiota composition and functional pathways in irritable bowel syndrome.Scientific reports · 2026Article
- Carpal tunnel syndrome as risk factor for subsequent development of irritable bowel syndrome: a retrospective cohort study.Scientific reports · 2026Article
- Frequency of FODMAP-rich products consumption and irritable bowel syndrome-like symptoms among amateur runners.Frontiers in nutrition · 2026Article
- Serum FGL2 is correlated with the severity and psychological status of diarrhea-predominant irritable bowel syndrome.Frontiers in medicine · 2026Article
- In the Mouth or in the Gut? Innovation Through Implementing Oral and Gastrointestinal Health Science in Chronic Pain Management.Journal of clinical medicine · 2025Article
- Targeting Irritable Bowel Syndrome Through Diet and Mechanism-Based Therapies: A Pathophysiological Approach.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIrritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction (DGBI) characterized by recurrent abdominal pain and altered bowel habits. Treatment typically focuses on symptom management without addressing underlying causes. This systematic review and meta-analysis aimed to explore the association between inflammatory markers and gut microbiome changes in individuals with IBS.
methodsA systematic search of PubMed, Scopus, EMBASE, and CINAHL databases was conducted in June 2024, identifying 41 studies that compared inflammatory markers and gut microbial composition in patients with IBS versus healthy controls. Meta-analysis was performed using a random-effects model, reporting standard mean differences (SMD) for inflammatory markers and mean differences (MD) for microbiome data, with 95% confidence intervals (CI).
resultsThe results showed significantly elevated pro-inflammatory markers in individuals with IBS, including Interleukin (IL)-6 (SMD = - 2.64), Tumor Necrosis Factor (TNF)-α (SMD = - 1.97), platelet-to-lymphocyte ratio (PLR, SMD = - 0.98), and fecal calprotectin (FC, SMD = - 0.42), while IL-10 was lower (SMD = 2.00). Microbiome analysis revealed increased Bacteroidetes (MD = - 15.92) and decreased Firmicutes (MD = 16.85) in people with IBS.
conclusionThese findings suggest that inflammation and gut microbial imbalance contribute to IBS, warranting further studies on their interplay and impact on the typical symptoms seen in IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.